Immuron Limited · ASX:IMC
Immuron — Emerging Growth Conference (September 2024)
18 slides from Immuron's conference presentation, Sep 26, 2024
Slide 1: Immuron CEO presentation to Emerging Growth Conference
Immuron CEO, Steven Lydeamore presentation to Emerging Growth Conference Melbourne, Australia, September 26 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore presented virtually at the Emerging Growth Conference early on 26 September 20
Slide 2: Immuron Platform Technology
Immuron Platform Technology Immuron’s proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. Immuron has the capability of producing highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine
Slide 3: References
References Connor P, Porter CK, Swierczewski B and Riddle MS. Diarrhea during military deployment: current concepts and future directions. Curr Opin Infect Dis. 25(5): 546-54; 2012. Hutton, M.L., Cunningham, B.A., Mackin, K.E. et al. Bovine antibodies targeting primary and recurrent Clostridium diff
Slide 4: Steven Lydeamore, Chief Executive Officer, September 2024
NASDAQ: IMRN ASX: IMC For personal use only Investor Presentation Steven Lydeamore Chief Executive Officer 26 September 2024
Slide 5: Safe Harbor Statement
SAFE HARBOR STATEMENT C e r ta i n state m e n t s m a d e i n t h i s p re s e nta t i o n a re fo r wa rd - l o o k i n g state m e n t s a n d a re b a s e d o n I m m u ro n ’s c u r re nt ex p e c tat i o n s , e st i m ate s a n d p ro j e c t i o n s . Wo rd s s u c h a s For personal use onl
Slide 6: Executive summary
Executive summary Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases For personal use only Company Overview Financial Snapshot Two commercially available
Slide 7: Travelan record sales
Travelan® record sales Global For personal use only + Full Year FY2024 AUD$4.9 million up 172% on (prior comparative period) pcp Net Sales A$'000 + June 2024 Quarter AUD$1.3 million up 277% on pcp and 5% on last quarter 6,000 5,000 Australia 4,000 + Full Year 2024 AUD$3.7 million up 236% on pcp + Ju
Slide 8: Addressable market & industry overview
* IMC Company Report - Travelan Market Analysis 2019 ** Centers for Disease Control and Prevention Yellow Book Addressable market & industry overview Billion Dollar Market For personal use only Traveller’s diarrhoea treatment market is large and growing at a CAGR of ~7%1 Industry tailwinds Travel pi
Slide 9: Addressable market & industry overview
Addressable market & industry overview Billion Dollar Market For personal use only Traveller’s diarrhoea treatment market is large and growing at a CAGR of ~7% 1 Industry tailwinds Travel picking up significantly following COVID lockdowns Frequent Symptom 30% - 70% of travelers experience traveller’
Slide 10: Immuron's clinical programs – opportunity assessment
IMMURON’S CLINICAL PROGRAMS – OPPORTUNITY ASSESSMENT › Immuron’s development of IMM-124E (hyperimmune › Infectious disease experts reacted favorably to the IMM-529 bovine colostrum) as a prescription medication has MOA, and its unique ability to target three elements of the rCDI infection – the spor
Slide 11: Technology platform
Technology platform Immuron’s proprietary technology platform For personal use only combines the natural human nutrition & health benefits of bovine colostrum with a novel class of specifically targeted oral polyclonal antibodies that offer delivery within the gastrointestinal (“GI”) tract and can b
Slide 12: Travelan | Mechanism of action
Travelan® | Mechanism of action Pre-Clinical Studies For personal use only Broad spectrum antimicrobial Protects against bacterial Binds to surface layer proteins Toxin neutralization and adhesion to host cell intestinal preventing bacterial clearance of targeted gut epithelia colonization and motil
Slide 13: Status of product portfolio and key milestones
Status of product portfolio and key milestones Travelan® Clostridioides difficile Immuron’s Clinical Programs For personal use only MTEC 21-10-013 grant Phase 2 IMM-529 randomized clinical challenge study to Prevention of recurrent CDI infections Compound or examine a dosing regimen for Travelan® Va
Slide 14: World first triple mechanism of action for CDI
WORLD FIRST TRIPLE MECHANISM OF ACTION FOR CDI IMM-529: pre-IND filed with FDA July 2024 Indication / Target IMM-529 will be indicated for the treatment of recurrent C. difficile For personal use only Population infection Product • Novel antibody-containing therapeutic which neutralizes C. difficile
Slide 15: Positive results support Travelan progress to phase 3
Positive results support Travelan® progress to phase 3 For personal use only IMM-124E Phase 2 + Healthy volunteers were recruited and randomized to receive a single daily oral Travelan® topline clinical dose of 1200 mg of Travelan® or placebo. Dosing commenced 2 days prior to trial results demonstra
Slide 16: IMM-124E Phase 3 strategy
IMM-124E Phase 3 strategy Pre 2H 2024 1H 2025 2H 2025 Post For personal use only Phase 1 clinical study Additional topline data Clinical Study Report Initiate Phase 3 Trial duration ~ 2 years (Baltimore, 1996) analysis August 2024 anticipated September 2024 End of Phase 3 FDA meeting Phase 2 clinica
Slide 17: Scientific references
Scientific references Travelan® (IMM-124E) For personal use only Travelan® has been shown to reduce both the incidence and severity of ETEC- Scandinavian Journal of Gastroenterology, 46:7-8, 862-868, DOI: 10.3109/00365521.2011.574726 induced diarrhea in up to 90% of volunteers Clinical Evaluation of
Slide 18: Steven Lydeamore contact information
For personal use only STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172
Immuron — Emerging Growth Conference (September 2024) on 6ix